This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
Dermatologists have long noted the need for a systemically administered drug designed to combat superficial infections of the skin due to fungi. Griseofulvin is the first such agent; its development appears to be assuming proportions of an historic nature.
In October, 1959, the Department of Dermatology of the University of Miami School of Medicine, through a grant from McNeil Laboratories, Inc., subsidiary of Johnson & Johnson, conducted a symposium on griseofulvin which was international in scope. Investigators from eleven countries reported on their experiences with the drug. Because of the widespread interest in the subject, this issue of the Archives is devoted entirely to the proceedings of that symposium.
Blank H. Introduction. AMA Arch Derm. 1960;81(5):649. doi:10.1001/archderm.1960.03730050005001
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: